NEW YORK (GenomeWeb News) – Exact Sciences today reported revenues for the first quarter were flat year over year, while its net loss more than doubled.

For the period ended March 31, the Madison, Wis.-based molecular diagnostics firm brought in revenues of $1.0 million, the same as a year ago, matching Wall Street estimates. All revenues for the quarter were derived from license fees. It had no product royalty fees in the quarter compared to $4,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.